ALX Oncology
ALXO
112 hedge funds and large institutions have $293M invested in ALX Oncology in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 26 reducing their positions, and 23 closing their positions.
75% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $1.9M
46% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 26
35% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 23
6% more funds holding
Funds holding: 106 → 112 (+6)
2.05% more ownership
Funds ownership: 91.3% → 93.35% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
43% less capital invested
Capital invested by funds: $510M → $293M (-$217M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.4M |
| 2 |
Millennium Management
New York
|
+$15.6M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$12.2M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$11.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$35M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$14.3M |
| 3 |
O
OrbiMed
New York
|
-$10.1M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$3.57M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.73M |
ALXO Hedge Fund Activity: Q2 2024 in Review
112 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2024, worth a combined $293M — down 43% from $510M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ALXO positions and 23 closed out — a net gain of 8 holders — while 38 added to existing stakes and 26 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $19.4M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $35M sold.
- 112 institutional investors held ALX Oncology (ALXO) as of Q2 2024, up from 106 in Q1 2024.
- Funds reported $293M of ALX Oncology stock for Q2 2024, down 43% quarter-over-quarter.
- 31 funds opened new ALX Oncology positions in Q2 2024 and 23 closed out, a net change of +8 holders.
- The largest ALX Oncology buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $19.4M added.
- The largest ALX Oncology seller in Q2 2024 was Cormorant Asset Management, an estimated $35M sold.
Based on aggregated 13F filings for Q2 2024.